Since altered expression of Nln has been documented in several disease conditions including stroke (Rashid et al., 2014), Alzheimer's disease (Teixeira et al., 2018), Parkinson's disease (Plum et al., 2020), and certain cancers (Mirali et al., 2020), it is plausible to suggest that expression of Nln is likely to be changed in COVID‐19 patients. Here, NLN is linked to COVID-19.